InsidersTradesSigma
Total declarations
Company
▲ Purchases (2 ops.)
▼ Sales (0 ops.)
Insider track record
CEODisclosed buys
2
Disclosed sells
0
T+90 hit rate
0%
T+90 mean return
-0.7%
Across 1 buy signal with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Browse the detailed record of transactions filed by Lewis Joel, Chief Executive Officer and President. Officer active across 1 company, notably Galectin Therapeutics INC. Aggregated, 81 reports have been published. Split: 2 buys · 0 sell. Total volume traded: €5k. History available since 30 April 2021. The latest transaction was filed on 2 January 2026 (Levée d'options). Regulator: SEC (Form 4). All data is openly available.
Companies and markets linked to Lewis Joel
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations81 total
84,000 shares0Common StockSEC:0001133416-26-000008:0
7,829 shares@ US$2.861.0% of flowCommon StockSEC:0001133416-25-000071:0
15,680 shares@ US$2.391.7% of flowCommon StockSEC:0001133416-25-000058:0
1,867 shares@ US$2.390.2% of flowCommon StockSEC:0001133416-25-000052:0
200 shares@ US$2.390.0% of flowCommon StockSEC:0001133416-25-000048:0
1,300 shares@ US$2.390.1% of flowCommon StockSEC:0001133416-25-000044:0
14,000 shares@ US$2.391.5% of flowCommon StockSEC:0001133416-25-000038:0
56,420 shares@ US$1.573.7% of flowCommon StockSEC:0001133416-25-000029:0
56,000 shares0Common StockSEC:0001133416-24-000070:0
1,000 shares@ US$3.390.1% of flowCommon StockSEC:0001133416-24-000040:0
Canonical exit: 23 Jul 2024 (T+90)
152,584 shares@ US$1.9612.0% of flowCommon StockSEC:0001133416-24-000032:0
11,606 shares@ US$1.660.8% of flowCommon StockSEC:0001133416-24-000002:0
12,042 shares@ US$1.600.8% of flowCommon StockSEC:0001133416-23-000089:0
9,880 shares@ US$1.950.8% of flowCommon StockSEC:0001133416-23-000087:0
10,303 shares@ US$1.870.8% of flowCommon StockSEC:0001133416-23-000085:0
9,444 shares@ US$2.040.8% of flowCommon StockSEC:0001133416-23-000083:0
9,585 shares@ US$2.010.8% of flowCommon StockSEC:0001133416-23-000081:0
10,035 shares@ US$2.010.8% of flowCommon StockSEC:0001133416-23-000079:0
10,035 shares@ US$1.920.8% of flowCommon StockSEC:0001133416-23-000077:0
10,947 shares@ US$1.761.0% of flowCommon StockSEC:0001133416-23-000073:0
11,010 shares@ US$1.750.8% of flowCommon StockSEC:0001133416-23-000071:0
12,042 shares@ US$1.600.8% of flowCommon StockSEC:0001133416-23-000069:0
12,844 shares@ US$1.500.8% of flowCommon StockSEC:0001133416-23-000067:0
11,820 shares@ US$1.630.7% of flowCommon StockSEC:0001133416-23-000063:0
13,380 shares@ US$1.440.8% of flowCommon StockSEC:0001133416-23-000061:0
25 of 81 declarations
About Lewis Joel
LEWIS JOEL is Chief Executive Officer and President at Galectin Therapeutics INC, where he is also President and CEO. The declarant has 81 filings in total, and across the 81 sampled filings, purchases total EUR 4590, sales total EUR 0, with filings dated from 2021-05-03 to 2026-01-06 and a modal transaction nature of Attribution.
